These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9352398)

  • 1. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.
    Gieschke R; Reigner BG; Steimer JL
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weibull prediction of event times in clinical trials.
    Ying GS; Heitjan DF
    Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Computer simulations to support drug therapy in children].
    Breddemann A; Läer S
    Med Monatsschr Pharm; 2008 Nov; 31(11):429-33. PubMed ID: 19055162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
    Kimko HC; Reele SS; Holford NH; Peck CC
    Clin Pharmacol Ther; 2000 Nov; 68(5):568-77. PubMed ID: 11103759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdialysis: an in vivo approach for measuring drug delivery in oncology.
    Brunner M; Müller M
    Eur J Clin Pharmacol; 2002 Jul; 58(4):227-34. PubMed ID: 12136367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling, prediction and adaptive adjustment of recruitment in multicentre trials.
    Anisimov VV; Fedorov VV
    Stat Med; 2007 Nov; 26(27):4958-75. PubMed ID: 17639505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and analysis of in vitro antitumor pharmacodynamic studies.
    Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power analyses for correlations from clustered study designs.
    Tu XM; Kowalski J; Crits-Christoph P; Gallop R
    Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
    Dallow NS; Leonov SL; Roger JH
    Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures.
    Wright MC; Taekman JM; Barber L; Hobbs G; Newman MF; Stafford-Smith M
    Contemp Clin Trials; 2005 Dec; 26(6):646-59. PubMed ID: 16226924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment.
    Abbas I; Rovira J; Casanovas J
    Contemp Clin Trials; 2007 May; 28(3):220-31. PubMed ID: 16979387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial simulation: a tool for understanding study failures and preventing them.
    Girard P
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):228-34. PubMed ID: 15733219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.